Compare Coupang Inc (CPNG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs GeneDx Holdings Corp — how do they compare? Coupang Inc trades at $15.82 (market cap $27.70B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Coupang Inc is far larger — about 13.7× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and GeneDx Holdings Corp for 19 Days on average.
| CPNG | WGS | |
|---|---|---|
Market Cap | $27.70B | $2.02B |
Volume | 27,703,608 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $167.51 |
52-Week Low | $13.75 | $34.51 |
Typical Hold Time | 55 Days | 19 Days |
Enterprise Value | $27.22B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.41, up 4.05% today, with a bullish technical signal and strong analyst support. Revenue grew to $34.53B in 2025, though recent quarterly EPS misses and a negative net income margin of -2.16% highlight profitability challenges. The stock is supported by positive cash flow from operations of $1.77B and a dominant e-commerce position in South Korea, but faces competitive pressure and a projected net loss in 2026.
The outlook balances high growth potential against near-term earnings volatility. Investment appeal lies in market dominance and analyst consensus price target of $25.25, implying significant upside, but risks include intense competition, regulatory scrutiny from U.S.-South Korea trade tensions (CNBC, 2026-08-31), and execution hurdles in expanding logistics networks.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
